SURROZEN INC (SRZN)
Health Care · Clinical-stage biopharmaceutical / oncology · NASDAQ
Surrozen is a clinical-stage biotech company developing Wnt pathway-targeted therapeutics for oncology and regenerative medicine.
What SURROZEN INC does
Surrozen is a biopharmaceutical company focused on discovering and developing therapeutic product candidates targeting the Wnt signaling pathway. The company leverages its proprietary drug discovery and development capabilities to create candidates for oncology and regenerative medicine applications. Surrozen is currently in clinical trials with its pipeline candidates and is working to obtain regulatory approval while managing its operations and seeking funding to support ongoing development activities.
Themes: ["clinical-stage oncology"]
Fundamentals
- Price$23.50 as of 2026-07-09 close
- Market cap$273M as of 2026-07-10
- 1-year return+176.0% as of 2026-07-09 close
- Net margin-4571.1% as of 2026-07-10
- ROE+58.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-35.6% as of 2026-07-10
- Beta0.56 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial initiation, cost, timing, progress and results remain uncertain and could delay or prevent regulatory approval and commercialization of product candidates"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.